Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Inhibitor of Nuclear Factor Kappa B Kise Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kise Beta or I Kappa B Kise 2 or IKBKB or EC 2.7.11.10) - Overview
Inhibitor of Nuclear Factor Kappa B Kise Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kise Beta or I Kappa B Kise 2 or IKBKB or EC 2.7.11.10) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Inhibitor of Nuclear Factor Kappa B Kise Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kise Beta or I Kappa B Kise 2 or IKBKB or EC 2.7.11.10) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Inhibitor of Nuclear Factor Kappa B Kise Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kise Beta or I Kappa B Kise 2 or IKBKB or EC 2.7.11.10) - Companies Involved in Therapeutics Development
EntreChem SL
IMMD Inc
Theralogics Inc
Inhibitor of Nuclear Factor Kappa B Kise Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kise Beta or I Kappa B Kise 2 or IKBKB or EC 2.7.11.10) - Drug Profiles
13-197 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EC-70124 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMD-0560 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit IKBKB for Inflammatory Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit IKBKB for Inflammation and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TLX-1423 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Inhibitor of Nuclear Factor Kappa B Kise Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kise Beta or I Kappa B Kise 2 or IKBKB or EC 2.7.11.10) - Dormant Products
Inhibitor of Nuclear Factor Kappa B Kise Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kise Beta or I Kappa B Kise 2 or IKBKB or EC 2.7.11.10) - Discontinued Products
Inhibitor of Nuclear Factor Kappa B Kise Subunit Beta (Nuclear Factor NF Kappa B Inhibitor Kise Beta or I Kappa B Kise 2 or IKBKB or EC 2.7.11.10) - Product Development Milestones
Featured News & Press Releases
Jan 17, 2018: EntreChem reports potent activity of EC-70124 in Acute Myeloid Leukemia
Mar 10, 2016: EntreChem’s orally active EC-70124 reverts tumorigenic and stem cell properties in prostate cancer
Dec 21, 2015: New EntreChem publication in Oncotarget describing activity of EC-70124 in colorectal cancer
Sep 26, 2014: EntreChem presents in ESMO 2014 congress: Activity of the multi-targeted kise inhibitor EC-70124 in colorectal cancer
Jun 02, 2014: EntreChem presents in 2014 ASCO Annual Meeting: Activity of the multi-targeted kise inhibitor EC-70124 in Triple Negative Breast Cancer
Apr 30, 2013: Entrechem Announces Presentation Of Positive Preclinical Results Of Orally Active Kise Inhibitor EC-70124 At 2013 AACR Annual Meeting
Mar 26, 2012: EntreChem’s Kise Inhibitor Shows Potential For Treatment Of Head And Neck Cancer
May 09, 2011: EntreChem’s Developmental Drug EC-70124 Creates New Strategy For Treatment Of Glioblastoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by EntreChem SL, H2 2019
Pipeline by IMMD Inc, H2 2019
Pipeline by Theralogics Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019